The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress).
 
David Lawrence Bajor
Consulting or Advisory Role - BridgeBio Pharma; Cardinal Health
Research Funding - Apexigen; Roche/Genentech; Seagen; Tesaro
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Honoraria - Foundation Medicine; Guardant Health
Consulting or Advisory Role - Exenex
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Eisai (Inst); GSB Pharma (Inst); Incyte (Inst); Johnson & Johnson (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Gina M. Vaccaro
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Exelixis; Incyte; Pfizer; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - Incyte
Research Funding - Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst)
 
Ashiq Masood
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - Astellas Pharma (Inst); Boston Biomedical (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Exelixis (Inst); Genentech/Roche (Inst); Ipsen (Inst); Macrogenics (Inst); Merck (Inst); Novocure (Inst); PRA Health (Inst); Proteus Digital Health (Inst); Seagen (Inst); Signatera (Inst); Tempus
 
Ursa Abigail Brown-Glaberman
Consulting or Advisory Role - Biotheranostics; Eisai; Novartis; Seagen
Research Funding - Seagen (Inst)
 
Juneko E. Grilley-Olson
Consulting or Advisory Role - Bayer; Chimerix
Research Funding - Genentech (Inst); MedImmune (Inst); NanoCarrier (Inst); Pfizer (Inst); Seagen (Inst)
 
Milind M. Javle
Consulting or Advisory Role - AstraZeneca; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Hedy L. Kindler
Honoraria - AstraZeneca
Consulting or Advisory Role - Aldeyra Therapeutics; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Deciphera; ERYTECH Pharma; Five Prime Therapeutics; Inventiva Pharma; Inventiva Pharma; ipsen; Kyowa Hakko Kirin; Merck; Paradox Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Polaris (Inst); Polaris (Inst); Roche/Genentech (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Olumide B. Gbolahan
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme
 
Anthony Frank Shields
Consulting or Advisory Role - Caris Life Sciences; ImaginAb; TransTarget
Speakers' Bureau - Caris Life Sciences
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; ImaginAb; Incyte; Inovio Pharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Taiho Pharmaceutical; Torque; Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; Merck; Newlink Genetics/Pharmatech; Oncomed; Seagen
 
Michael W. Schmitt
Employment - Seagen
Stock and Other Ownership Interests - Seagen; TwinStrand Biosciences
Patents, Royalties, Other Intellectual Property - Inventor on patents relating to high accuracy DNA sequencing held by the University of Washington, with an associated revenue sharing agreement.
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme